SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
CleanCore Solutions announced a comprehensive strategic pivot from a cleaning products and digital asset treasury company to an AI critical infrastructure company, including a non-binding letter of intent to acquire majority ownership in a data center project (the Midwest Project) and plans to explore selling its legacy cleaning products business and Dogecoin holdings to redeploy capital into data center and computing infrastructure.
View raw filing on EDGAR →CleanCore Solutions entered into a Controlled Equity Offering Sales Agreement on June 8, 2026, authorizing the sale of up to $750 million in common stock through Cantor Fitzgerald and Curvature Securities. This is a material dilutive issuance under an at-the-market offering structure (Item 1.01), representing a substantial potential equity raise that would significantly dilute existing shareholders. The filing also discloses termination of a prior ATM agreement and payments to prior agents, confirming the capital-raising intent.
View raw filing on EDGAR →This disclosure describes the completion of a SPAC IPO and related private placements, including the exercise of an over-allotment option. While the IPO itself occurred on May 18, 2026 (prior to this 8-K filing), this Item 8.01 confirms the subsequent over-allotment exercise on May 20-21, 2026, and the resulting capital raised ($175.875 million in trust). This is a material capital-raising event for a blank-check company, but it does not fit neatly into the standard taxonomy categories (not an earnings release, M&A activity, or other specific event types). The disclosure is material to investors assessing the company's capitalization and ability to pursue a business combination.
View raw filing on EDGAR →The filing discloses a favorable appellate court decision in Melinta Therapeutics, LLC, et al. v. Nexus Pharmaceuticals, Inc., where the U.S. Court of Appeals for the Federal Circuit affirmed that Nexus's generic minocycline product infringed two of CorMedix's patents and rejected the invalidity challenge. This is a material litigation outcome that protects the Company's intellectual property and competitive position, warranting disclosure under Item 7.01 as a material event.
View raw filing on EDGAR →Solidion Technology entered into a Securities Purchase Agreement on June 7, 2026, to issue 750,000 shares of common stock and pre-funded warrants to purchase 1,583,000 additional shares in a private placement under Section 4(a)(2) and Rule 506(b) exemptions, raising approximately $32 million in net proceeds. This unregistered equity issuance materially increases share count and dilutes existing shareholders.
View raw filing on EDGAR →Keystone Acquisition Corp. consummated its IPO on June 4, 2026, raising $287.5 million through the issuance of 28.75 million units and entering into multiple definitive agreements (underwriting, warrant, trust, and registration rights agreements) central to the company's formation and capitalization as a special purpose acquisition company.
View raw filing on EDGAR →Keystone completed a private placement of 8,468,750 unregistered warrants to the Sponsor and Representatives for $8.47 million in gross proceeds, simultaneously with the IPO closing on June 4, 2026, with favorable terms including cashless exercise and registration rights.
View raw filing on EDGAR →Three independent directors—Speaker John A. Boehner, Paul Y. Cho, and Martin Payne—were appointed to the Board effective June 2, 2026, in connection with the IPO, with committee assignments and equity compensation of 25,000 to 40,000 Class B ordinary shares each.
View raw filing on EDGAR →Keystone adopted an Amended and Restated Memorandum and Articles of Association in connection with the IPO on June 2, 2026, reflecting governance document changes required for the newly public company.
View raw filing on EDGAR →InterPrivate Investment Partners V completed its initial public offering on June 5, 2026, raising $201.25 million in gross proceeds through the sale of 20.125 million units. The transaction involved entry into multiple material definitive agreements including underwriting, warrant, registration rights, and administrative agreements that govern the company's capital structure and governance.
View raw filing on EDGAR →The company completed a private placement of 540,000 units (365,000 to Sponsor and 175,000 to underwriters) at $10.00 per unit, generating $5.4 million in gross proceeds. The units, structured as a non-public offering exempt under Section 4(a)(2) of the Securities Act, include Class A ordinary shares and warrants, creating direct equity dilution.
View raw filing on EDGAR →Nicholaos C. Krenteras and Dimitri Goulandris were appointed to the board of directors effective June 3, 2026, resulting in a three-member board. Indemnity agreements were also entered into with multiple parties in connection with the appointments.
View raw filing on EDGAR →The Board approved a bylaw amendment reducing the stockholder meeting quorum requirement from a majority (>50%) to 35% of voting power. While bylaw amendments are often routine, this particular change materially affects the governance rights and voting mechanics available to shareholders by lowering the threshold needed to conduct stockholder business. This modification could be material to investors assessing corporate governance and shareholder protections, though it does not fit neatly into the more specific event categories.
View raw filing on EDGAR →The filing discloses results of the Company's 2026 Annual Meeting of Shareholders held on June 5, 2026, with detailed voting tabulations for four proposals: election of five directors (Proposal 1), approval of bylaw amendment establishing a staggered board structure (Proposal 2), ratification of HTL International, LLC as independent auditor (Proposal 3), and adjournment authority (Proposal 4). Item 5.07 explicitly presents certified voting results from Broadridge Financial Solutions, Inc., the appointed Inspector of Elections, making this a classic shareholder_vote_results disclosure. The bylaw amendment establishing board classification is material to governance structure and investor assessment.
View raw filing on EDGAR →New Providence Acquisition Corp. III entered into material definitive agreements with co-CEOs Gary Smith and Alexander Coleman to issue $1.5 million in unsecured promissory notes with conversion rights into equity units at $10.00 per unit, creating a dilutive financing arrangement with registration rights that materially affects the registrant's capitalization structure.
View raw filing on EDGAR →BSTR Newco, LLC entered into a Business Combination Agreement with Cantor Equity Partners I, Inc. (a SPAC), involving a change of control through merger. The transaction is supported by an effective S-4 registration statement (filed June 5, 2026), private placement investments, and a proxy statement/prospectus mailed to shareholders for voting, creating direct financial obligations via convertible notes and preferred stock issuances.
View raw filing on EDGAR →Bluejay Diagnostics completed a private placement on June 5, 2026, issuing pre-funded warrants, Series G warrants, and Series H warrants to purchase up to 10,967,751 shares of common stock for approximately $7.7 million in gross proceeds to accredited investors under Section 4(a)(2) and Rule 506.
View raw filing on EDGAR →The filing discloses a material acquisition/business combination transaction in which Real Asset Acquisition Corp. (RAAQ) is combining with IQM Finland Oy, resulting in IQM becoming a publicly traded company. The core event is the announcement that the Form F-4 Registration Statement has been declared effective by the SEC on June 5, 2026, and the definitive proxy statement/prospectus has been mailed to shareholders for voting at an Extraordinary General Meeting. This represents a change of control and material M&A activity under Item 1.01/2.01 framework, even though disclosed under Item 8.01.
View raw filing on EDGAR →The filing discloses the appointment of Freddy J. Martinez to the Board of Directors as a Class III director effective June 6, 2026, filling a newly created vacancy. The disclosure emphasizes his 40+ years of experience in investment management and corporate finance with particular focus on oil and gas and cross-border transactions, directly aligned with the Company's stated strategic focus on "oil & gas opportunities in Venezuela." This is a material appointment of a qualified director to guide the Company's business combination strategy.
View raw filing on EDGAR →Ribbon Acquisition Corp. disclosed under Item 8.01 that it deposited $125,000 into its trust account to extend the deadline for completing its initial business combination by one month (from May 15, 2026 to June 15, 2026). This extension is material to shareholders because it directly affects the timeline for the SPAC's merger or acquisition activity and the risk of liquidation if no business combination is consummated by the extended deadline. While this is a routine SPAC extension mechanism, the disclosure of a specific extension payment and revised deadline is material to investors' assessment of the company's status and timeline.
View raw filing on EDGAR →FutureCorp Space Acquisition 1 consummated its IPO on June 4, 2026, raising $230 million through the sale of 23 million units and executing ancillary agreements (underwriting, warrant, trust, registration rights, and private placement agreements) in connection with the capital-raising event. As a SPAC, the IPO represents a material capital event that will fund future M&A activity.
View raw filing on EDGAR →FutureCorp Space Acquisition 1 completed a private placement of 6,000,000 warrants to the Sponsor and Representative simultaneously with IPO closing, sold at $1.00 per warrant under Section 4(a)(2) exemption. The unregistered sale of equity securities exercisable for Class A ordinary shares is material to investors assessing post-IPO capitalization and ownership structure.
View raw filing on EDGAR →Three independent directors—David J. Anderman, Shawn K. Pelsinger, and John R. Tuttle—were appointed to the Board in connection with the IPO on June 4, 2026, with assignments to key board committees (Audit, Compensation, and Nominating and Corporate Governance). This appointment establishes the governance structure and committee leadership of the newly public company.
View raw filing on EDGAR →The Amended and Restated Memorandum and Articles of Association became effective and were filed with the Cayman Islands Registrar in connection with the IPO on June 4, 2026. The transition to public company governance documents is material to investors, though the disclosure is largely procedural with full terms referenced in the Registration Statement.
View raw filing on EDGAR →The filing discloses OCC approval for a deposit acquisition by Axos Bank, a material M&A transaction previously disclosed on April 23, 2026, with expected closing later in 2026. This represents a significant corporate development affecting the registrant's asset base and business scope, meeting the materiality threshold for a reasonable investor.
View raw filing on EDGAR →aTyr Pharma received a deficiency notice on December 4, 2025, for failing to maintain a minimum closing bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). Although the company was granted a second 180-day compliance period (until November 30, 2026) on June 3, 2026, the filing explicitly states that failure to regain compliance by that date will result in a delisting notice, with only the possibility of appeal. This is a material delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the June 5, 2026 Annual Meeting of Stockholders under Item 5.07. The filing presents final voting tallies for four proposals: election of nine directors (including one designated by Apax Investor), advisory approval of executive compensation, and ratification of KPMG LLP as independent auditor. These are routine but material governance matters that affect board composition and auditor appointment.
View raw filing on EDGAR →Neurogene announced completion of dosing in its EmboldenTM registrational trial for NGN-401 in Rett syndrome treatment. This is a material clinical development milestone for a gene therapy company, as completion of a Phase 3 registrational trial dosing is a significant de-risking event that affects investor assessment of the company's pipeline and regulatory pathway. However, it does not fit neatly into the standard taxonomy categories (not earnings, M&A, litigation, impairment, or other defined event types), warranting classification as other_material.
View raw filing on EDGAR →The filing discloses a press release providing an update on a "previously announced process to evaluate strategic alternatives" for the registrant. This language suggests ongoing M&A or restructuring activity, but the Item 7.01 disclosure is vague and does not specify the nature, status, or outcome of the strategic review. Without access to the attached press release (Exhibit 99.1), the precise event type cannot be determined; however, strategic alternatives processes typically involve potential M&A, divestitures, or going-concern considerations that would be material to investors. Classified as other_material pending review of the exhibit.
View raw filing on EDGAR →Catheter Precision entered into a Securities Purchase Agreement to acquire 2,941,176 shares of Volato Group common stock for $1,000,000 in a private placement transaction. While this is technically an investment by the Company rather than an issuance of the Company's own securities, the filing is disclosed under Item 1.01 (Material Definitive Agreement) and involves a material equity transaction with significant value ($1M purchase price plus ~$1.1M in consideration received). The transaction is material to investors as it represents a substantial deployment of capital and involves equity securities with inherent valuation risk.
View raw filing on EDGAR →BioCardia sold 3,509,604 shares at $1.279 per share pursuant to an "At The Market" offering agreement with H.C. Wainwright & Co. This is a classic dilutive equity issuance under an ATM facility, which materially increases share count and dilutes existing shareholders. ATM offerings are a standard disclosure category under Item 3.02, though disclosed here under Item 8.01.
View raw filing on EDGAR →The Company issued a press release reporting "corrected financial results" for the three and nine months ended March 31, 2026, in connection with filing an Amended Form 10-Q/A. This is a disclosure of quarterly financial results, which falls squarely within the earnings_release category. The fact that the results are "corrected" (implying a prior error) makes this material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes on three proposals: election of seven directors, ratification of Wipfli LLP as independent auditor, and approval of a Stock Plan amendment to increase authorized shares by 200,000. All three proposals passed with clear majorities, and the disclosure includes detailed vote tallies (FOR, AGAINST, WITHHELD, ABSTAIN, BROKER NON-VOTE) for each matter.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Fuel Tech's Annual Meeting of Stockholders held on June 4, 2026. The filing reports voting outcomes on three proposals: election of four directors (Vincent J. Arnone, Douglas G. Bailey, Sharon L. Jones, and Dennis L. Zeitler), ratification of RSM US LLP as independent auditor, and an advisory vote on executive compensation, with detailed vote tallies for each matter. This is a quintessential Item 5.07 disclosure and is material to investors as it confirms board composition and auditor appointment.
View raw filing on EDGAR →The filing discloses the appointment of Yasir Haider as Chief Financial Officer effective June 3, 2026, a principal financial officer role. While James Clavijo's departure from the CFO position is mentioned, the principal disclosed action centers on Haider's appointment to this material executive position. CFO appointments are material to investors as they affect financial reporting oversight and governance.
View raw filing on EDGAR →Rick Dunn, the Chief Financial Officer, is stepping down from his position at the conclusion of a transition period following a mutual agreement with the Company. While the disclosure also includes severance terms (base salary continuation, COBRA, and RSU acceleration), the principal disclosed action is the departure of a named executive officer. The CFO role is material to investor assessment of the company's financial management and governance.
View raw filing on EDGAR →This Item 5.07 discloses the complete results of Appian's June 3, 2026 annual stockholder meeting, including voting outcomes on five proposals: election of eight directors, ratification of BDO USA as independent auditor, advisory approval of named executive officer compensation, frequency of future advisory compensation votes, and approval of the amended 2017 Equity Incentive Plan. The detailed vote tallies for each proposal and director nominee are material to investors assessing corporate governance and capital allocation decisions.
View raw filing on EDGAR →The filing discloses a delisting compliance matter under Nasdaq Listing Rule 5450(a)(1) regarding the Minimum Bid Price Requirement. Although the Company has now regained compliance as of June 5, 2026, the disclosure centers on the prior non-compliance notice (December 22, 2025) and the resolution of that delisting risk. This is a material event affecting the Company's listing status and investor confidence, even though the immediate threat has been resolved.
View raw filing on EDGAR →SI-BONE held its Annual Meeting of Stockholders on June 8, 2026, with shareholders voting on three proposals: election of directors (Jeffrey W. Dunn and John G. Freund, M.D.), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of executive compensation. All three matters passed.
View raw filing on EDGAR →Groupon appointed Aditya Rajkumar as Chief Operating Officer, effective August 3, 2026, with a compensation package including a $500,000 base salary, cash bonuses, and equity awards of 155,000 shares.
View raw filing on EDGAR →The filing discloses the separation of Mannix Aklian, Chief Commercial Officer and Global Head of Software Sales and Marketing, formalized through a transition and separation agreement dated June 5, 2026. While the disclosure includes detailed severance and compensation terms, the principal disclosed action is Aklian's departure from the Company. The separation of a C-suite executive responsible for commercial operations and sales is material to investors' assessment of the registrant's leadership and business continuity.
View raw filing on EDGAR →The filing discloses a 1-for-40 reverse stock split effected on June 3, 2026, explicitly stated as being undertaken "solely to enable the Company to expeditiously restore compliance with the continued listing standards of the Nasdaq Stock Market...and Nasdaq's $1.00 minimum bid price requirements." This is a classic delisting-risk mitigation action—the company's stock price had fallen below Nasdaq's minimum bid price threshold, triggering the need for a reverse split to avoid delisting. The materiality is clear: failure to maintain listing compliance would be terminal to the company's public status.
View raw filing on EDGAR →Volato Group entered into a Securities Purchase Agreement on June 7, 2026, to sell 6,500,000 shares of Class A common stock at $0.34 per share to institutional investors, raising approximately $2.21 million in gross proceeds. The filing explicitly discloses this under Item 1.01 (Material Definitive Agreement) and Item 3.02 (Unregistered Sales of Equity Securities), with the securities offered in reliance on Section 4(a)(2) and Regulation D exemptions. This is a classic dilutive private placement that materially increases share count and affects existing shareholders' ownership percentage.
View raw filing on EDGAR →The filing discloses entry into a material secured loan agreement (Item 1.01) with Agile Capital Funding, LLC on May 27, 2026, for approximately $260,000 borrowed with ~$389,740 total due over 32 weeks. While this creates a direct financial obligation (Item 2.03), it does not fit cleanly into the covenant_breach category (no breach alleged) or dilutive_issuance (debt, not equity). The subordinated nature and short repayment term suggest financial stress, but the event is best classified as a material financing arrangement outside the standard taxonomy.
View raw filing on EDGAR →Tonix announced entry into an agreement with a group purchasing organization (GPO) providing coverage for TONMYA® to approximately 17 million U.S. commercially insured individuals, effective June 1, 2026. This represents a significant commercial milestone for the company's product, expanding market access beyond the ~75 million Medicaid beneficiaries already covered. While this is a material commercial development affecting the company's market opportunity and competitive position, it does not fit neatly into the standard 8-K event taxonomy (not M&A, not an executive change, not a financial restatement or impairment), warranting classification as other_material.
View raw filing on EDGAR →The filing discloses the issuance of 109,588,265 shares of Class A common stock in exchange for 3,870,000 shares of Series C Preferred Stock on June 5, 2026. This represents a massive dilutive equity issuance that increased outstanding shares from approximately 55.3 million to 164.9 million—a nearly 3x increase. The stated purpose was to regain Nasdaq compliance and reduce stockholders' deficit, indicating financial distress. While technically an exchange rather than a cash raise, the economic substance is a highly dilutive issuance to existing shareholders.
View raw filing on EDGAR →Vivos Therapeutics received a Nasdaq notice on June 5, 2026, that it failed to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) from April 23 to June 4, 2026. The company has been granted a 180-day compliance period (until December 2, 2026) to regain compliance, with potential for a second 180-day period if certain conditions are met.
View raw filing on EDGAR →Vivos Therapeutics completed an unregistered private placement of a convertible promissory note (the "V-Co 4 Note"), exempt from registration under Section 4(a)(2) of the Securities Act, which is convertible into common stock and creates dilution to existing shareholders.
View raw filing on EDGAR →Ocean Power Technologies entered into a Securities Purchase Agreement on June 4, 2026, to sell 25,000,000 shares of common stock at $0.40 per share, together with 25,000,000 common warrants, for aggregate gross proceeds of $10.0 million. This is a registered direct offering of equity securities with significant dilution to existing shareholders. The warrants are exercisable at $0.40 per share and expire six years after initial exercise, further diluting equity. This is a classic dilutive equity issuance disclosed under Item 1.01.
View raw filing on EDGAR →The Company disclosed that the DOE reinstated a Grant and extended the project and budget periods. This represents a material positive development for a battery technology company — reinstatement of federal funding and project extension would affect investor assessment of the company's financial resources and operational runway. However, the Item 7.01 disclosure is deliberately non-specific about the grant amount, original terms, or financial impact, and the actual press release content is not provided in the excerpt. Without those details, the event does not fit cleanly into earnings_release, ma_activity, or other more specific categories, warranting classification as other_material.
View raw filing on EDGAR →